DaVita Inc
XMUN:TRL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DaVita Inc
XMUN:TRL
|
US |
|
Fujikura Ltd
F:FJK
|
JP |
|
R
|
Re/Max Holdings Inc
F:2RM
|
US |
|
C
|
Cigna Corp
XBER:CGN
|
US |
|
S
|
Sociedad Quimica y Minera de Chile SA
XBER:QYM
|
CL |
|
N
|
Newmont Corporation
F:NMM
|
US |
|
Sibanye Stillwater Ltd
F:47VS
|
ZA |
DaVita Inc
DaVita is a healthcare company focused on kidney care. Its main business is running dialysis centers, where it treats patients whose kidneys can no longer clean waste from the blood properly. It also offers related care services for people with chronic kidney disease, including support before dialysis starts and help managing long-term treatment. The company makes most of its money by billing health insurers, government programs, and other payers for dialysis treatments and related care. Its main customers are patients with kidney failure and the healthcare systems that cover their treatment, especially those who need repeat, ongoing care rather than a one-time service. Because dialysis is usually needed several times a week, DaVita’s business is built around steady, recurring patient visits. What makes DaVita’s role distinct is that it sits in a very specific and essential part of the healthcare chain: it turns kidney disease treatment into a large-scale service network. Instead of selling a product, it provides a specialized medical service that depends on trained staff, clinic operations, and close coordination with doctors and insurers. That makes it a focused operator in a niche but critical area of healthcare.
DaVita is a healthcare company focused on kidney care. Its main business is running dialysis centers, where it treats patients whose kidneys can no longer clean waste from the blood properly. It also offers related care services for people with chronic kidney disease, including support before dialysis starts and help managing long-term treatment.
The company makes most of its money by billing health insurers, government programs, and other payers for dialysis treatments and related care. Its main customers are patients with kidney failure and the healthcare systems that cover their treatment, especially those who need repeat, ongoing care rather than a one-time service. Because dialysis is usually needed several times a week, DaVita’s business is built around steady, recurring patient visits.
What makes DaVita’s role distinct is that it sits in a very specific and essential part of the healthcare chain: it turns kidney disease treatment into a large-scale service network. Instead of selling a product, it provides a specialized medical service that depends on trained staff, clinic operations, and close coordination with doctors and insurers. That makes it a focused operator in a niche but critical area of healthcare.
Beat: DaVita said first-quarter results came in ahead of expectations, helped by better treatment volume, stronger revenue per treatment, and lower patient care costs.
Guidance up: The company raised and narrowed 2026 adjusted operating income guidance to $2.15 billion to $2.25 billion and lifted adjusted EPS guidance to $14.10 to $15.20 per share.
Volume better: Full-year treatment growth guidance was increased from flat to 25 to 50 basis points, partly due to better underlying performance and partly from patient transfers tied to Fresenius clinic closures.
ACA better, but early: ACA enrollment is trending slightly better than expected versus a prior about $40 million headwind, but management said it is too early to change the assumption because enrollment mix and affordability effects are still developing.
Tech investment: Management emphasized continued investment in IT and AI, citing tools like ScheduleHub and saying the work should support longer-term clinical and operational performance.
